(MENAFN- GlobeNewsWire - Nasdaq) The report offers key market opportunities in PTSD clinical trials by providing insights into global trial distribution, enrollment trends, and prominent drugs. It aids in identifying strategic locations, understanding trial success rates, and generating data-driven strategies for competitive advantage in the global market.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Post-Traumatic Stress Disorder (PTSD) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets's offering.
This report provides top line data relating to the clinical trials on Post-Traumatic Stress Disorder (PTSD). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Report Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• The analyst Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Post-Traumatic Stress Disorder (PTSD) to Central Nervous System Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Post-Traumatic Stress Disorder (PTSD) Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Post-Traumatic Stress Disorder (PTSD)
• Oct 20, 2025: Reconnect Labs Reaches Key Milestone in Phase 2 Study of RE03 for PTSD-Related Sleep Disturbances
• Sep 24, 2025: Synendos Therapeutics Reports Positive and Highly Promising Topline Results From Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
• Sep 16, 2025: MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
• Sep 08, 2025: PharmAla Completes Import of LaNeo MDMA for US Distribution
• Sep 02, 2025: Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
• Aug 28, 2025: Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications
• Aug 19, 2025: Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(B)(2) Pathway
• Aug 12, 2025: SVN-SDN-14 PTSD Programme - Positive pre-clinical results with three high-performing candidates advancing to in vivo studies
• Clinical Trial Profile Snapshots

Companies Featured

• Multidisciplinary Association for Psychedelic studies
• Johnson & Johnson
• The Lundbeck Foundation
• GSK plc
• Tonix Pharmaceuticals Holding Corp
• Neuphoria Therapeutics Inc
• Otsuka Holdings Co Ltd
• Thermo Fisher Scientific Inc
• C. H. Boehringer Sohn AG & Co KG
• Idorsia Ltd

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110420309